Literature DB >> 18759359

The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it?

Christopher H Hawkes1.   

Abstract

It is frequently assumed that idiopathic Parkinson's disease starts with several nonmotor symptoms and signs, but the evidence for this stage in the disease process is of variable quality. This review evaluates the more robust prospective or pathologically confirmed publications to establish whether there is a premotor period and if so what is its duration. The most informative studies are considered to be those concerned with olfaction, dysautonomia, and sleep disorder. Estimates for the duration of the prodromal phase vary from months to decades. It is concluded that there probably is an early phase in the disease where a variety of nonmotor features develop, but the sequence and time of onset of such features is not well established. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18759359     DOI: 10.1002/mds.22242

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  46 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

3.  Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease.

Authors:  Tyler M Rolheiser; Heather G Fulton; Kimberley P Good; John D Fisk; J Roger McKelvey; Christophe Scherfler; Naeem M Khan; Ronald A Leslie; Harold A Robertson
Journal:  J Neurol       Date:  2011-02-03       Impact factor: 4.849

Review 4.  Precision medicine for disease modification in Parkinson disease.

Authors:  Alberto J Espay; Patrik Brundin; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

5.  Alterations of the brain network in idiopathic rapid eye movement sleep behavior disorder: structural connectivity analysis.

Authors:  Kang Min Park; Ho-Joon Lee; Byung In Lee; Sung Eun Kim
Journal:  Sleep Breath       Date:  2018-10-12       Impact factor: 2.816

6.  Occurrence of depression and anxiety prior to Parkinson's disease.

Authors:  E L Jacob; N M Gatto; A Thompson; Y Bordelon; B Ritz
Journal:  Parkinsonism Relat Disord       Date:  2010-08-01       Impact factor: 4.891

7.  Depression and subsequent risk of Parkinson disease: A nationwide cohort study.

Authors:  Helena Gustafsson; Anna Nordström; Peter Nordström
Journal:  Neurology       Date:  2015-05-20       Impact factor: 9.910

8.  Personality characteristics and motor skills attributed to occupations in Parkinson disease.

Authors:  Nicole M Gatto; Yvette Bordelon; Margaret Gatz; Beate Ritz
Journal:  Cogn Behav Neurol       Date:  2011-03       Impact factor: 1.600

9.  Parkinson disease. Unravelling the nonmotor mysteries of Parkinson disease.

Authors:  K Ray Chaudhuri; Anna Sauerbier
Journal:  Nat Rev Neurol       Date:  2016-01       Impact factor: 42.937

10.  Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients.

Authors:  Hai Jun Li; Ying Yu; Ying Chen; Hai Yan Liang
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.